VIATRIS INC. Proceeds from (Repayments of) Short-term Debt
VIATRIS INC. (VTRS) reported Proceeds from (Repayments of) Short-term Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfShortTermDebt · last filed 2026-08-06
- VIATRIS INC. proceeds from (repayments of) short-term debt for the quarter ending 2026-06-30 was $0.00.
- VIATRIS INC. proceeds from (repayments of) short-term debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. proceeds from (repayments of) short-term debt for the quarter ending 2025-12-31 was -$1.50M.
- VIATRIS INC. proceeds from (repayments of) short-term debt for the quarter ending 2025-09-30 was $300.00K, a 80.00% decline year-over-year.
- VIATRIS INC. proceeds from (repayments of) short-term debt for fiscal 2025 was $200.00K.
- VIATRIS INC. proceeds from (repayments of) short-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- VIATRIS INC. proceeds from (repayments of) short-term debt for fiscal 2023 was $300.00K.
- VIATRIS INC. proceeds from (repayments of) short-term debt for fiscal 2022 was -$1.49B, a 480.82% decline from fiscal 2021.
| Period end | Proceeds from (Repayments of) Short-term Debt 3 month | Proceeds from (Repayments of) Short-term Debt 6 month | Proceeds from (Repayments of) Short-term Debt 9 month | Proceeds from (Repayments of) Short-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | -$1.50M derived: sum of 3 quarters · filed 2026-08-06 | -$1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | -$1.50M derived: sum of 2 quarters · filed 2026-05-07 | -$1.20M derived: sum of 3 quarters · filed 2026-05-07 | -$1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.20M derived: sum of 2 quarters · filed 2026-02-26 | -$1.20M derived: sum of 3 quarters · filed 2026-08-06 | $200.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $300.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.70M 10-Q · filed 2025-11-06 | $200.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.40M 10-Q · filed 2026-08-06 | -$100.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.40M 10-Q · filed 2026-05-07 | -$100.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.40M derived: sum of 3 quarters · filed 2026-05-07 | $1.40M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.50M derived: sum of 2 quarters · filed 2025-11-06 | $1.50M 10-Q · filed 2025-11-06 | $1.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $100.00K derived: sum of 3 quarters · filed 2026-02-26 | -$22.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $100.00K derived: sum of 2 quarters · filed 2026-02-26 | -$22.80M derived: sum of 3 quarters · filed 2026-02-26 | -$204.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$22.80M derived: sum of 2 quarters · filed 2026-02-26 | -$204.30M derived: sum of 3 quarters · filed 2026-02-26 | $300.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$22.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$204.40M derived: sum of 2 quarters · filed 2024-11-07 | $200.00K 10-Q · filed 2024-11-07 | -$500.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$181.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $23.10M 10-Q · filed 2024-08-08 | -$477.30M derived: sum of 3 quarters · filed 2025-02-27 | -$996.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $204.60M 10-Q · filed 2024-05-09 | -$295.80M derived: sum of 2 quarters · filed 2025-02-27 | -$815.10M derived: sum of 3 quarters · filed 2025-02-27 | -$450.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$500.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$1.02B derived: sum of 2 quarters · filed 2025-02-27 | -$655.30M derived: sum of 3 quarters · filed 2025-02-27 | -$1.49B 10-K · filed 2025-02-27 |
| 2022-09-30 | -$519.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$154.90M derived: sum of 2 quarters · filed 2023-11-08 | -$992.80M 10-Q · filed 2023-11-08 | -$1.21B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $364.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$473.50M 10-Q · filed 2023-08-07 | -$687.50M derived: sum of 3 quarters · filed 2024-02-28 | -$281.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$837.90M 10-Q · filed 2023-05-08 | -$1.05B derived: sum of 2 quarters · filed 2024-02-28 | -$645.50M derived: sum of 3 quarters · filed 2024-02-28 | $618.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$214.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $192.40M derived: sum of 2 quarters · filed 2024-02-28 | $1.46B derived: sum of 3 quarters · filed 2024-02-28 | $392.10M 10-K · filed 2024-02-28 |
| 2021-09-30 | $406.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.67B derived: sum of 2 quarters · filed 2022-11-07 | $606.10M 10-Q · filed 2022-11-07 | $1.71B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $1.26B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $199.70M 10-Q · filed 2022-08-08 | $1.30B derived: sum of 3 quarters · filed 2023-02-27 | $1.30B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$1.06B 10-Q · filed 2022-05-09 | $35.40M derived: sum of 2 quarters · filed 2023-02-27 | $35.70M derived: sum of 3 quarters · filed 2023-02-27 | $35.70M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.10B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.10B derived: sum of 2 quarters · filed 2023-02-27 | $1.10B derived: sum of 3 quarters · filed 2023-02-27 | $1.10B 10-K · filed 2023-02-27 |
| 2020-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $300.00K derived: sum of 2 quarters · filed 2021-11-08 | $300.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$1.80M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$44.40M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |